Enanta Pharmaceuticals Q4 revenue rises, helped by higher sales of AbbVie's MAVYRET/MAVIRET

Enanta Pharmaceuticals

17/11/2025 21:13

Overview

Enanta fiscal Q4 revenue missed analyst expectations

Net loss for fiscal Q4 narrows year-over-year, indicating improved financial performance

Company maintains "strong" cash position, bolstered by October 2025 public offering

Outlook

Enanta plans to file IND for EPS-3903 in the second half of 2026

Company expects cash and revenue to fund operations into fiscal 2029

Enanta to submit IND for EDP-978 in Q1 2026

Result Drivers

ABBVIE SALES - Increase in quarterly revenue attributed to higher sales of AbbVie's MAVYRET®/MAVIRET®

REDUCED R&D EXPENSES- Research and development expenses were $23.8 million for the three months ended September 30, 2025, compared to $30.8 million for the three months ended September 30, 2024

REDUCED G&A EXPENSES- General and administrative expenses totaled $9.7 million for the three months ended September 30, 2025, compared to $13.7 million for the three months ended September 30, 2024.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$15.13 mln
$15.96 mln (6 Analysts)
Q4 Net Income
-$18.7 mln
Q4 Operating Expenses
$33.51 mln
Q4 Operating Income
-$18.39 mln
Q4 Pretax Profit
-$18.67 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 39.7% above its November 14 closing price of $12.06

Press Release: ID:nBwqQ3yLa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)